Evidence & regulatory context
- Mechanism
- Secreted laminin-related axon-guidance protein signalling through DCC and UNC5 receptors; no ChEMBL entity (protein). FLAGGED: n_trials deliberately left 0. The only interventional netrin-1 programme is NP137 (NCT02977195), a humanised ANTI-netrin-1 blocking antibody in advanced solid tumours - the pharmacological opposite of netrin-1 delivery - so it was NOT recorded as translation evidence. The remaining 15 hits are serum netrin-1 biomarker studies, not netrin-1 administration.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOtherC57BL/6Tail vein injectionPretreatment before the 18-hour decompression exposure
Model: Hypobaric hypoxia-induced lung injury produced by exposure to hypobaric stress at 340 mmHg for 30 minutes followed by 260 mmHg for 6, 12, 18 or 24 hours, with 18 hours selected as the injury exposure
Eighteen hours of hypobaric hypoxia produced the greatest bronchoalveolar protein leakage together with neutrophil infiltration, septal thickening, oedema and activation of the intrinsic apoptosis pathway. Netrin-1 pretreatment reduced protein leakage, inhibited neutrophil migration, lowered the in…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
